

## MELAN ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/ Support	STUDY	O R P E E G N	ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	DATE OF FIRST REG.	# of ACT. INSTs	# of CURR IRBs	
						LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS				
SWOG	S1320-Adv, BRAF mut, Inter v Contin	1	Y 1	Lead-in Continuous Dosing	280	171	59	34	14	5	1	09/19/2014	246	110
						171	59	34	14	5	1			
		2	Y 2	Continuous Dosing	280	70	23	16	7	2	1	09/19/2014		
				3 Intermittent Dosing		70	25	11	6	4	2			
						140	48	27	13	6	3			
	S1404-Melan, Adv, HD-IFN/Ipilimumab vs MK-3475	1	N 1	Tissue for PD-L1 testing	1378	1426	992	470	213	0	0	11/10/2015	392	172
						1426	992	470	213	0	0			
		2	Y 2	FDA approved regimen	1378	678	488	243	118	21	1	11/10/2015		
				3 MK-3475 (Pembrolizumab)		667	484	243	110	20	0			
						1345	972	486	228	41	1			
	S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro)	1	Y 1	MK-3475 (pembrolizumab)	77	3	3	2	2	0	0	02/06/2017	73	31
						3	3	2	2	0	0			
Yes	EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	1	E	Total Registrations		19	12	4	3	2	2	11/03/2015	336	143
						19	12	4	3	2	2			
		2	E	Total Registrations		5	4	2	2	1	0	11/03/2015		
						5	4	2	2	1	0			
	EA6141-Melan, Adv, Nivolumab+Ipi ± Sargmostim	1	E	Total Registrations		36	27	18	4	0	0	03/25/2016	299	123
						36	27	18	4	0	0			
No	E3612-MELAN, Adv Ipilimumab±Bevacizumab	1	E	Total Registrations		6	2	1	1	1	0	02/16/2015	138	50
						6	2	1	1	1	0			

**MELAN Open Studies with No Registrations**

<u>Study</u>	<u>Registration/Phase</u>	<u>Open Date</u>
S1616 MELAN,, Adv, Ipilimumab ± Nivolumab	1 Randomization	17-Jul-17